DAMATO, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.538
AS - Asia 2.469
EU - Europa 2.057
SA - Sud America 524
AF - Africa 75
OC - Oceania 18
Totale 8.681
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.473
RU - Federazione Russa 863
SG - Singapore 699
IT - Italia 667
CN - Cina 601
BR - Brasile 428
HK - Hong Kong 281
VN - Vietnam 272
KR - Corea 207
IE - Irlanda 170
BD - Bangladesh 120
FR - Francia 81
IN - India 66
ID - Indonesia 60
FI - Finlandia 56
DE - Germania 52
GB - Regno Unito 47
AR - Argentina 43
SE - Svezia 42
CA - Canada 32
JP - Giappone 31
NL - Olanda 24
TH - Thailandia 23
IQ - Iraq 21
CI - Costa d'Avorio 20
EC - Ecuador 19
AU - Australia 18
MX - Messico 18
UA - Ucraina 18
MA - Marocco 15
PH - Filippine 15
ZA - Sudafrica 14
MY - Malesia 13
CO - Colombia 11
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
NG - Nigeria 8
EG - Egitto 6
PE - Perù 6
PK - Pakistan 6
AT - Austria 5
ES - Italia 5
TR - Turchia 5
BE - Belgio 4
BJ - Benin 4
CL - Cile 4
HN - Honduras 4
IR - Iran 4
KE - Kenya 4
KZ - Kazakistan 4
PY - Paraguay 4
SA - Arabia Saudita 4
UY - Uruguay 4
AZ - Azerbaigian 3
LB - Libano 3
LT - Lituania 3
OM - Oman 3
PL - Polonia 3
PS - Palestinian Territory 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AL - Albania 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HU - Ungheria 2
JM - Giamaica 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
GR - Grecia 1
IS - Islanda 1
JO - Giordania 1
KH - Cambogia 1
NO - Norvegia 1
PR - Porto Rico 1
QA - Qatar 1
RE - Reunion 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
Totale 8.681
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.540
Singapore 537
Ashburn 411
Hong Kong 237
Seoul 204
Dublin 168
Hefei 167
Milan 121
Ho Chi Minh City 112
Los Angeles 110
San Jose 89
Kent 81
Altamura 80
Lawrence 80
Council Bluffs 78
Beijing 72
Hanoi 63
Buffalo 62
Rome 60
Moscow 59
Lauterbourg 55
Fairfield 47
Boston 46
Chicago 43
Jakarta 42
Princeton 41
São Paulo 38
Florence 37
The Dalles 37
New York 35
Mumbai 33
Tokyo 27
Helsinki 25
Munich 24
Wilmington 24
Bangkok 23
Shanghai 23
Lappeenranta 21
Naples 21
Abidjan 20
Salt Lake City 20
San Diego 18
Turin 18
Dallas 17
Melbourne 17
Frankfurt am Main 16
London 16
Seattle 14
Toronto 13
Baghdad 12
Figino 12
Genoa 12
Verona 12
West Jordan 12
Casablanca 10
Da Nang 10
Hillsboro 10
Quito 10
Rio de Janeiro 10
Tianjin 10
Turku 10
Woodbridge 10
Elk Grove Village 9
Goiânia 9
Orem 9
Tampa 9
Tashkent 9
Belo Horizonte 8
Bengaluru 8
Bologna 8
Curitiba 8
Guangzhou 8
Haiphong 8
Medford 8
Miano 8
Pune 8
Yubileyny 8
Abuja 7
Atlanta 7
Bari 7
Brasília 7
Cambridge 7
Dulles 7
Guarulhos 7
Kuala Selangor 7
Manila 7
Montreal 7
Padua 7
Andover 6
Brooklyn 6
Denver 6
Johannesburg 6
Kuala Lumpur 6
Lima 6
Miami 6
Palermo 6
Porto Alegre 6
Salvador 6
San Francisco 6
Shenzhen 6
Totale 5.556
Salva come PNG Salva come JPEG
Nome #
Teaching Video NeuroImage: The “Chameleon Eyes Sign” in Myasthenia Gravis 283
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis 251
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 223
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 190
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 186
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis 186
Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis 171
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 170
Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report 165
Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders 161
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors 157
Conventional and emerging treatments and controversies in myasthenia gravis 148
Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders 147
Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome 146
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 146
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis 145
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 143
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 143
Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors 139
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology 136
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 135
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: A case series of 22 patients 134
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 131
Serological and experimental studies in different forms of myasthenia gravis 129
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 129
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 128
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 126
Benefit and danger from immunotherapy in myasthenia gravis 125
The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders 124
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 123
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia 122
Myasthenia gravis and related disorders 120
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet 118
Eculizumab improves fatigue in refractory generalized myasthenia gravis 118
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 117
Myasthenia gravis with antibodies to MuSK: An update 115
Diagnostic algorithms in autoimmune encephalitis 112
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 112
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 111
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 109
Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma 109
Anorexia heralding the onset of neuromyelitis optica 108
Creutzfeldt-Jakob disease manifesting as stroke mimic in a 78-year-old patient: Pitfalls and tips in the diagnosis 108
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 107
3,4-Diaminopyridine may improve myasthenia gravis with M u SK antibodies 107
Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection 106
Heterogeneity in myasthenia gravis: considerations for disease management 106
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 104
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study 104
In reply 102
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 101
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 101
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 100
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 98
Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations 98
When myasthenia gravis is not all 97
Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab 97
Type 1 immune response in progressive multiple sclerosis 95
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4 93
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 89
Response to: “MuSK-positive myasthenia may be triggered not only by SARS-CoV-2” 88
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 88
Neuropathic pain in CASPR2 antibody disease spectrum: A systematic review 86
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 83
Epidemiology of seropositive myasthenia gravis in Sardinia: A population‐based study in the district of Sassari 82
Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing 49
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice 48
Validation of the "Patient-Acceptable Symptom State" Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study 44
Validation of the MOG-AR Score 43
Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study 39
Typical and atypical clinical presentations 38
Cellular immune endophenotypes separating early and late-onset myasthenia gravis 23
Real-Life Evaluation of the MOGAD Diagnostic Criteria 23
The gut microbiome associated with LGI1 ‐antibody encephalitis 21
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management 20
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota 19
Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay 19
Brain [18F]FDG-PET as a marker of disease activity in a case of CASPR2 limbic encephalitis 18
Uveitis: A snapshot in the MOG antibody spectrum 15
Neurological adverse events of immune checkpoint inhibitors: A practical guide to diagnosis with a focus on neuroimaging findings 15
Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology 14
Totale 8.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 0 0 0 0 0 0 104 24 1 14 75
2022/2023491 68 161 16 17 0 89 89 3 19 10 13 6
2023/2024402 11 17 68 17 33 40 15 63 9 35 72 22
2024/20253.495 94 316 158 395 1.040 735 107 92 120 57 236 145
2025/20264.110 347 436 557 591 310 87 287 210 279 265 210 531
2026/202763 63 0 0 0 0 0 0 0 0 0 0 0
Totale 8.779